- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/40 - Mineralocorticosteroids, e.g. aldosteroneDrugs increasing or potentiating the activity of mineralocorticosteroids
Patent holdings for IPC class A61P 5/40
Total number of patents in this class: 40
10-year publication summary
2
|
4
|
0
|
4
|
3
|
0
|
3
|
1
|
3
|
1
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Ardelyx, Inc. | 113 |
4 |
F. Hoffmann-La Roche AG | 7930 |
3 |
Hoffmann-La Roche Inc. | 3408 |
3 |
Arrowhead Pharmaceuticals, Inc. | 299 |
2 |
Eli Lilly and Company | 3840 |
2 |
Ono Pharmaceutical Co., Ltd. | 434 |
2 |
Genesis Pharma SA | 7 |
2 |
Glaxo Group Limited | 4089 |
1 |
Bayer Schering Pharma AG | 389 |
1 |
Bayer Pharma AG | 1061 |
1 |
Takeda Pharmaceutical Company Limited | 2714 |
1 |
Angion Biomedica Corp. | 61 |
1 |
Apeptico Forschung und Entwicklung GmbH | 34 |
1 |
Arana Therapeutics (Vic) Pty Ltd | 2 |
1 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 700 |
1 |
Daiichi Sankyo Company, Limited | 1862 |
1 |
Dainippon Sumitomo Pharma Co., Ltd. | 195 |
1 |
Ivashchenko, Andrey Alexandrovich | 15 |
1 |
KBP Biosciences Co., Ltd. | 29 |
1 |
Medshine Discovery Inc. | 601 |
1 |
Other owners | 9 |